Why the study?
Is the angiotensin II type 1 receptor (AT1R) A1166C gene polymorphism associated with the risk of end-stage renal disease?
Is the angiotensin II type 1 receptor (AT1R) A1166C gene polymorphism associated with the risk of end-stage renal disease?
Answers are grounded in this paper and cite their sources.
The AT1R A1166C gene polymorphism does not appear to be associated with the risk of end-stage renal disease in overall, Caucasian, or Asian populations.
The association between angiotensin II type 1 receptor (AT1R) A 1166C (rs5186) gene polymorphism and end-stage renal disease (ESRD) risk remains controversial. We aimed to assess the association between AT1R A1166C gene polymorphism and ESRD susceptibility by performing a meta-analysis. Eligible studies were searched according to a predefined criterion using electronic databases. Eight articles were identified for the analysis of the association between AT1R A1166C gene polymorphism and ESRD risk. A allele and AA genotype were not associated with ESRD risk in overall populations, Caucasians and Asians (overall populations: p = 0.834 and 0.832, Caucasians: p = 0.853 and 0.884, Asians: p = 0.243 and 0.982). CC and AC genotype were not associated with ESRD risk in overall populations, Caucasians and Asians (overall populations: p = 0.304 and 0.712, Caucasians: p = 0.510 and 0.987, Asians: p = 0.319 and 0.225). In conclusion, AT1R A1166C gene polymorphism may not be correlated with ESRD risk in overall populations, Caucasians and Asians. However, more studies should be performed in the future.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: